2 completed, 2 terminated, 1 unknown. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow sonepcizumab: new trials by email Literature Review of sonepcizumab trials Research Report on sonepcizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma ASONEP - Renal Cell Carcinoma | Phase 2 | Terminated | Lpath, Inc. | 40 | 2013-02-01 | 2016-01-20 |
| Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea - Exudative Age-related Macular Degeneration | Phase 2 | Completed | Lpath, Inc. | 158 | 2012-08-01 | 2016-10-17 |
| iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) iSONEP (sonepcizumab/LT1009) - Pigment Epithelial Detachment | Phase 1 | Terminated | Lpath, Inc. | 12 | 2011-03-01 | 2013-04-23 |
| Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration iSONEP - Neovascular Age Related Macular Degeneration | Phase 1 | Unknown | Lpath, Inc. | 15 | 2008-10-01 | 2012-04-16 |
| Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors ASONEP (sonepcizumab/LT1009) - Solid Tumors | Phase 1 | Completed | Lpath, Inc. | 37 | 2008-04-01 | 2012-01-31 |
Carcinoma, Renal Cell (1) · Choroidal Neovascularization (1) · Macular Degeneration (1) · Neoplasms (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Detachment (1)
Lpath, Inc. (5)
United States (5)
Glenn Stoller, MD (2) · Dario A Paggiarino, MD (1) · Susan Hazel (1) · William Garland, PhD (1)